Core Insights - Eli Lilly and Company has built up an inventory of $1.5 billion for its experimental oral weight-loss drug, orforglipron, in anticipation of an FDA decision expected in April, marking a significant increase from nearly $550 million last year [1] - The FDA has granted a fast-track review voucher for the weight-loss pill, potentially reducing the approval timeline to one or two months, compared to the usual 10 to 12 months for most new drugs [2] - Eli Lilly aims to have sufficient supply to launch the weight-loss pill across multiple countries simultaneously, pending U.S. approval [2] Financial Performance - Eli Lilly's stock has increased by 19.09% over the past year, with a recent rise of 2.27% to close at $1,038.27 [3] - Benzinga's Edge Rankings place Eli Lilly in the 90th percentile for quality and the 84th percentile for momentum, indicating strong performance relative to peers [3]

Group 1 - BeOne Medicines AG (NASDAQ:ONC) is recognized as a high growth international stock, with a Buy rating and a price target of $414 from Bernstein and $394 from Barclays [1][2][4] - The company received the first-in-world approval for its drug Sonrotoclax in China, aimed at treating relapsed/refractory mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL) [2][4] - The MCL study showed a 52.4% overall response rate (ORR) and the CLL/SLL study demonstrated a 77% ORR, indicating strong efficacy of Sonrotoclax [4] Group 2 - Management emphasizes that the approval in China is part of a global rollout strategy for BeOne Medicines AG [4] - Bernstein's Rebecca Liang believes the company's pipeline is undervalued and highlights Sonrotoclax as having potential best-in-class status [4] - BeOne Medicines AG is a global oncology company focused on innovative cancer treatments for hematology and solid tumors [4]

By Kane Wu and Andrew Silver HONG KONG/SHANGHAI, Feb 13 (Reuters) - Global drugmakers are stepping up their search for China‑developed experimental medicines as they cut costs ahead of patent expirations, with industry analysts predicting licensing deals will surge to a fresh record this year. The value of such deals signed by ‌companies in the greater China region - which includes Hong Kong, Macau and Taiwan - rose nearly tenfold last year from 2021 to an unprecedented $137.7 billion, according ‌to data ...

Group 1 - The FTSE 100 Index is maintaining a tight range near its all-time high, influenced by the financial results of major British companies [1] - Key companies such as Barratt, Redrow, AstraZeneca, BP, and Barclays have recently published their financial results [1] - The index showed volatility following the release of a relatively weak GDP report by the Office of National Statistics (ONS) [1]

Core Viewpoint - KDventures AB has strengthened its financial position and is well-positioned to support its portfolio companies in developing new treatments for significant medical needs [1]. Significant Events During the Fourth Quarter - Dilafor received a US patent for its drug candidate tafoxiparin, which is advancing to phase 3 clinical development [2]. - PharmNovo obtained approval to start a phase 2a clinical trial for PN6047, a treatment for neuropathic pain, aligned with FDA requirements [2]. - SVF Vaccines reported positive preclinical results for its immunotherapy SVF-001 targeting chronic hepatitis B and D [2]. - KDventures participated in a SEK 7.5 million financing round for BOOST Pharma, which raised a total of SEK 15 million for its stem cell therapy BT-101 [2]. - BOOST Pharma presented new long-term data from the BOOSTB4 trial for BT-101 at an international conference [2]. - Modus Therapeutics received regulatory approval to initiate the second part of its phase 2 study for sevuparin in chronic kidney disease [2]. - AnaCardio reported positive results from the phase 2a trial of AC01 for heart failure, meeting its primary endpoint [2]. - SVF Vaccines signed a non-binding letter of intent for a reverse takeover with Novakand Pharma, aiming for a Nasdaq First North Premier listing [3]. Financial Update Fourth Quarter - KDventures reported a net loss of SEK -39.6 million for Q4 2025, compared to SEK -18.6 million in Q4 2024 [6]. - The total fair value of the portfolio decreased to SEK 1,327.4 million from SEK 1,346.7 million in the previous quarter [6]. - Net asset value at the end of December 2025 was SEK 1,044.7 million, down from SEK 1,245.0 million at the end of December 2024 [6]. Financial Update Full-Year - For the full year 2025, KDventures reported a net loss of SEK -193.9 million, compared to SEK -8.1 million in 2024 [10]. - The total fair value of the portfolio decreased to SEK 1,327.4 million from SEK 1,451.5 million in 2024 [10]. - KDventures invested SEK 61.8 million in portfolio companies during 2025, down from SEK 62.0 million in 2024 [10].

Core Insights - The pharmaceutical company announced that phase 3 trials demonstrated that Vanrafia effectively slowed the decline in kidney function for adults suffering from progressive autoimmune kidney disease, specifically IgA nephropathy [1] Group 1 - The phase 3 trials indicate a positive outcome for Vanrafia in treating IgA nephropathy [1] - The drug targets a specific demographic, namely adults with progressive autoimmune kidney disease [1] - The results may position the company favorably in the competitive landscape of kidney disease treatments [1]

Core Insights - Novartis announced final results from the Phase III ALIGN study, demonstrating that Vanrafia (atrasentan) significantly slows the decline in kidney function in adults with IgA nephropathy (IgAN) [1][3][9] - The study showed a difference of 2.39 ml/min/1.73m in estimated glomerular filtration rate (eGFR) change from baseline compared to placebo at Week 136, with a nominal p-value of 0.057 [1][9] - Vanrafia is positioned as a foundational therapy for IgAN, with a consistent safety profile and the ability to integrate into existing treatment plans [3][8] Study Results - At Week 132, Vanrafia demonstrated a 2.59 ml/min/1.73m change in eGFR from baseline compared to placebo, with a nominal p-value of 0.039 [2][9] - The ALIGN study provides the longest follow-up period in pivotal Phase III studies for IgAN, confirming the efficacy of Vanrafia across multiple timepoints and measures of kidney function [3][9] Product Information - Vanrafia is the first and only selective endothelin A receptor antagonist approved for primary IgAN, administered as a once-daily oral treatment [7][8] - It can be used alongside existing supportive care without the need for titration and does not require a Risk Evaluation and Mitigation Strategy (REMS) program [8] Company Commitment - Novartis is advancing its multi-asset IgAN portfolio, which includes Fabhalta (iptacopan) and investigational compound zigakibart, aiming to address significant unmet needs in kidney health [4][11] - The company has a legacy of over 40 years in kidney disease treatment and is focused on developing therapies that target the underlying causes of kidney diseases [11][12]

Core Insights - Organon reported $6.2 billion in revenue and $1.9 billion in adjusted EBITDA for 2025, with a 3% decline in revenue on both reported and ex-FX basis, although the biosimilar franchise performed better than expected, particularly driven by HADLIMA [2][3][4] Revenue and Financial Performance - The company guided for approximately $6.2 billion in revenue and $1.9 billion in adjusted EBITDA for 2026, indicating a stable outlook compared to 2025 [3][20] - Adjusted gross margin is expected to decline by about 75–100 basis points in 2026, primarily due to higher cost of goods sold [21] - Organon reported a Q4 2025 net loss of $205 million, influenced by a $301 million goodwill impairment, while non-GAAP adjusted net income was $165 million for Q4 and $954 million for the full year [16][17] Biosimilars and Product Performance - The biosimilars segment, particularly HADLIMA, grew approximately 61% ex-FX in 2025, with expectations for flat to modest growth in 2026 [4][11][12] - The company launched a denosumab biosimilar in the U.S. in late September 2025, contributing to the biosimilars growth [11] - Nexplanon received FDA approval to extend its duration from three to five years, but management anticipates a volume headwind due to policy-driven access changes and a shift in reinsertions [5][9][10] Strategic Focus and Outlook - Organon aims to stabilize revenue, maintain profitability, and continue deleveraging, with a target of net leverage below 4.0x by the end of 2026 [3][18] - The company plans to reduce its dividend payout ratio to support debt reduction and has divested the JADA System, generating approximately $390 million in net proceeds [18][20] - Management expects interest expense of about $500 million and depreciation of about $140 million for 2026, with a non-GAAP tax rate projected between 27.5% and 29.5% [22]

Core Viewpoint - Sanofi's new CEO, Belén Garijo, faces significant challenges in revitalizing the company's drug pipeline and addressing investor concerns, particularly regarding the reliance on the eczema treatment Dupixent, which constitutes over 30% of revenues [1] Group 1: Leadership Transition - Belén Garijo, previously CEO of Merck KGaA, will become Sanofi's first female CEO and the only woman leading a large-cap global drugmaker after GSK's Emma Walmsley stepped down [1] - Garijo's appointment follows the resignation of Paul Hudson, whose efforts to turn around Sanofi were hindered by a lack of new blockbuster drugs, leading to a 25% decline in Sanofi's stock over the past year [1] Group 2: Drug Pipeline Challenges - Sanofi's primary challenge is to replace Dupixent, as the company has not identified a successor drug ahead of patent expirations in the early 2030s, which has negatively impacted share prices [1] - Vaccine sales, which account for nearly 20% of revenues, have also declined, exacerbated by a more skeptical attitude towards vaccines from the U.S. health administration [1] Group 3: R&D and Investor Expectations - Investors and analysts emphasize the need for Garijo to enhance R&D productivity, as her previous tenure at Merck KGaA was marked by mixed results in drug development, with only three new drugs launched [1] - Garijo is recognized for her operational execution and detail-oriented approach, but there are concerns about her ability to reinvigorate Sanofi's R&D department given her stronger background in operations than in scientific research [1]

- Improved profitability across each business segment - Future strategic direction now clearly defined FEBRUARY 13, 2026 © Kirin Holdings Company, Limited Implementation of Strategic Path (KV2027) Clearly on Track KV2027 REVIEW Blackmores and FANCL acquisitions solidified Health Science as our third growth engine Kirin Group Long-Term Vision Our Vision for 2035 and a Clear Path towards Maximizing Corporate Value ENVIRONMENTAL OUTLOOK Preparing for Structural Shifts We will operate our business based on the ...